Clomiphene citrate raises testosterone in men with secondary hypogonadism by stimulating the hypothalamus and pituitary rather than replacing testosterone directly. The practical advantage is that it maintains or can restore fertility, because it does not suppress the HPG axis the way exogenous testosterone does. For younger men with low testosterone who have not yet had children or who want to preserve the option, clomiphene is a meaningful alternative to standard TRT.

Clomiphene is not FDA-approved for male hypogonadism, its approval is for female infertility. Male prescribing is off-label, which is legal and common in clinical practice. It is widely used by urologists and endocrinologists for this purpose.

How Clomiphene Works in Men

Clomiphene is a selective estrogen receptor modulator (SERM). It blocks estrogen receptors in the hypothalamus and pituitary. This blocking action removes the negative feedback that estrogen normally exerts on GnRH and LH secretion. With that feedback lifted, the pituitary produces more LH and FSH. LH then stimulates the Leydig cells in the testes to produce more testosterone, and FSH stimulates sperm production.

The result is elevated testosterone produced by the testes themselves, not delivered from outside, along with preserved or enhanced spermatogenesis.

Who Is a Candidate

Clomiphene works only in secondary hypogonadism, where the problem is inadequate signaling from the brain rather than testicular failure. If LH and FSH are elevated and testosterone is low (primary hypogonadism), the testes cannot respond to additional stimulation and clomiphene will not work.

The ideal candidate for clomiphene-based treatment:

  • Secondary hypogonadism confirmed by low testosterone + low or inappropriately normal LH/FSH
  • Wants to preserve or restore fertility
  • Has not been on anabolic steroids for an extended period (which can blunt pituitary response)
  • Does not have a pituitary adenoma requiring other treatment

What the Evidence Shows

The evidence base for clomiphene in male hypogonadism is smaller than for TRT but consistent in direction. Multiple prospective studies and retrospective analyses show testosterone increases of 50-200% from baseline in men who respond to clomiphene.

A 2012 prospective study in 86 hypogonadal men found that clomiphene citrate at 25-50 mg every other day increased mean testosterone from 249 ng/dL to 610 ng/dL over three months, with improvement in sexual symptoms. FSH and LH rose appropriately, and no safety signals were observed.

A comparison study published in BJU International found that testosterone levels and symptom scores on clomiphene were comparable to injectable testosterone, though individual response varied more with clomiphene.

No large randomized controlled trial comparing clomiphene to TRT in hypogonadal men exists. The off-label status of clomiphene for male use has limited industry funding for such trials.

Dosing

The typical dosing protocol for male secondary hypogonadism:

  • 25 mg daily or 25-50 mg every other day
  • Some clinicians use 50 mg three times per week
  • Response is assessed at 4-8 weeks with repeat testosterone testing

Response varies significantly between individuals. Some men reach mid-to-high normal testosterone ranges; others see modest improvements. Non-responders, those who do not raise testosterone into the therapeutic range after dose adjustment, generally require TRT.

Side Effects

Clomiphene raises estrogen as well as testosterone, because more testosterone is available for aromatization. This can produce estrogen-related symptoms in some men:

  • Nipple sensitivity or gynecomastia (breast tissue growth), uncommon but reported
  • Mood changes, some men report irritability or emotional lability
  • Visual disturbances, a class effect of SERMs; any visual changes require immediate evaluation and discontinuation

Unlike TRT, clomiphene does not suppress the HPG axis. Stopping clomiphene allows natural testosterone production to return, usually within a few weeks.

Enclomiphene: The Purified Version

Clomiphene citrate is a mixture of two isomers: enclomiphene (trans-clomiphene) and zuclomiphene (cis-clomiphene). Enclomiphene is the isomer responsible for the testosterone-raising effect; zuclomiphene is associated with more side effects and a longer half-life that can cause accumulation with repeated dosing.

Enclomiphene acetate (Androxal) has been studied specifically for male hypogonadism and performed well in clinical trials, though it has not received FDA approval for this use as of early 2026. Compounded enclomiphene is available through some specialty pharmacies and telehealth programs.

For more on what distinguishes secondary from primary hypogonadism, see What Is Hypogonadism? Primary vs. Secondary Explained. For a comparison with standard TRT delivery methods, see Testosterone Injections vs. Gel: Which Delivery Method Is Better?.